心血宁片联合缬沙坦氢氯噻嗪治疗原发性高血压的疗效观察

目的 探讨心血宁片联合缬沙坦氢氯噻嗪治疗原发性高血压的临床疗效。方法 选取2021年3月—2022年3月上海交通大学医学院附属新华医院收治的116例原发性高血压患者，按照随机数字表法分为对照组和治疗组，每组各58例。对照组口服缬沙坦氢氯噻嗪片，1片/次，1次/d。治疗组在对照组治疗基础上口服心血宁片，4片/次，3次/d。两组疗程12周。观察两组疗效及主要症状消失率。比较治疗前后两组诊室血压[收缩压（SBP）、舒张压（DBP）]，24 h动态血压指标及杜氏高血压生活质量量表、世界卫生组织生活质量测定简表（WHOQOL-BREF）评分。结果 治疗后，治疗组总有效率是96.55%，较对照组86.21%显著提高（P＜0.05）。治疗后，两组诊室SBP、DBP均较治疗前显著下降（P＜0.05）；治疗后，治疗组诊室SBP、DBP低于对照组（P＜0.05）。治疗后，两组24 h SBP、24 h DBP、白天SBP（dSBP）、白天DBP（dDBP）、夜间SBP（nSBP）、夜间DBP（nDBP）24 h平均动脉压（24 h MAP）、24 h SBP变异系数（24 h SBPCV）、24 h DBP变异系数（24 h DBPCV）均较治疗前显著降低（P＜0.05）；且以治疗组降低更显著（P＜0.05）。治疗后，治疗组头晕目眩、头痛、胸闷的消失率分别是94.83%、89.66%、79.31%，均显著高于对照组的86.21%、75.86%、62.07%（P＜0.05）。治疗后，两组杜氏高血压生活质量量表评分、WHOQOL-BREF评分均显著增加（P＜0.05），且治疗后，治疗组杜氏高血压生活质量量表评分、WHOQOL-BREF评分均高于对照组（P＜0.05）。结论 心血宁片联合缬沙坦氢氯噻嗪治疗原发性高血压整体效果确切，可有效获得血压的稳定控制及症状的明显缓解，促进患者生活质量的改善，值得临床推广应用。

Clinical observation of Xinxuening Tablets combined with valsartan and hydrochlorothiazide in treatment of essential hypertension

Objective To explore the clinical efficacy of Xinxuening Tablets combined with valsartan and hydrochlorothiazide in treatment of essential hypertension. Methods A total of 116 patients with essential hypertension admitted to Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine from March 2021 to March 2022 were selected and divided into control group and treatment group according to random number table method, with 58 patients in each group. Patients in the control group were po administered with Valsartan and Hydrochlorothiazid Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Xinxuening Tablets on the basis of the control group, 4 tablets/time, three times daily. Both groups were treated for 12 weeks. The curative effect and the disappearance rate of main symptoms were observed in the two groups. The blood pressure (SBP), diastolic blood pressure (DBP), 24 h ambulatory blood pressure index, Duhenn Hypertension Quality of Life Scale and WHOQOL-BREF score were compared between two groups before and after treatment. Results After treatment, the total effective rate of treatment group was 96.55%, which was significantly higher than that of control group 86.21% (P＜0.05). After treatment, SBP and DBP in two groups were significantly decreased compared with before treatment (P＜ 0.05). After treatment, SBP and DBP in treatment group were lower than those in control group (P＜0.05). After treatment, 24 h SBP, 24 h DBP, daytime SBP (dSBP), daytime DBP (dDBP), night SBP (nSBP), night DBP (nDBP) 24 h mean arterial pressure (24 h MAP), 24 h SBP coefficient of variation (24 h SBPCV), 24 h variation coefficient of DBP (24 h DBPCV) was significantly decreased compared with that before treatment (P＜0.05). The decrease was more significant in treatment group (P＜0.05). After treatment, the disappearance rates of dizziness, dizziness, headache and chest distress in treatment group were 94.83%, 89.66% and 79.31%, respectively, which were significantly higher than 86.21%, 75.86% and 62.07% in control group (P＜ 0.05). After treatment, the Duhenna hypertension Quality of life scale score and WHOQOL-BREF score of both groups were significantly increased (P＜ 0.05), and after treatment, the Duhenna hypertension quality of life scale score and WHOQOL-BREF score of the treatment group were higher than those of control group (P＜0.05). Conclusion Xinxuening Tablets combined with valsartan and hydrochlorothiazide has a definite overall effect in treatment of essential hypertension, and can effectively obtain stable control of blood pressure and obvious relief of symptoms, promote the improvement of patients’ quality of life, which is worthy of clinical application.